New Companies
Filter News
Found 4,081 articles
-
Pheon Therapeutics launched with $63 million in Series A financing and a vision of ushering in the next generation of antibody-drug conjugates.
-
Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
9/28/2022
Johnson & Johnson took another step forward in establishing two independent, market-leading companies with the announcement of Kenvue as the name for the planned New Consumer Health Company.
-
Zhongchao Inc. Establishes Chongqing Xinjiang Pharmaceutical Co., Ltd. to Improve Patient Access to Medications
9/28/2022
Zhongchao Inc. announced the establishment of Chongqing Xinjiang Pharmaceutical Co., Ltd. which mainly engages in pharmaceutical import and export trade, OME production, medical consumables operation, and pharmaceutical internet services.
-
Colossal started the “de-extinction” of the thylacine, commonly known as the Tasmania tiger. Now with a $30 million investment, this technology is gaining more traction.
-
September 24 is World Cancer Research Day, and September is Childhood Cancer Awareness Month. BioSpace spoke with leaders from three companies tackling pediatric glioma.
-
Actylis Debuts, Signaling the Creation of an Integrated Global Specialty Ingredients Manufacturing and Sourcing Powerhouse
9/26/2022
Actylis, a leading global manufacturer and sourcing expert of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, made its debut.
-
Metagenomi Named an Endpoints 11 Winner
9/22/2022
Metagenomi, a genetic medicines company with a versatile portfolio of wholly-owned, next-generation gene editing tools, today announced that it was selected as one of this year’s 11 most promising private biotechnology companies by John Carroll, founder and editor of Endpoints News.
-
Affini-T Therapeutics Named to the 2022 Endpoints 11
9/22/2022
Affini-T Therapeutics, Inc ., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, has been selected by Endpoints News Editor John Carroll as one of the most promising startups in biotech for his annual report on the Endpoints 11.
-
Mammoth Biosciences Named as an “Endpoints 11” Most Promising Startup of 2022
9/22/2022
Mammoth Biosciences , a biotech company harnessing next-generation CRISPR technology to detect and cure disease, has been chosen by Endpoints News Editor John Carroll as one of the most promising biotech startups for this year’s Endpoints 11 annual special report.
-
Odyssey Therapeutics Named to 2022 Endpoints 11
9/22/2022
Odyssey Therapeutics, Inc. today announced that it is has been named by Endpoints News as one of the Endpoints 11 companies of 2022.
-
Endpoints News Announces the 11 Most Promising Biotech Startups of 2022
9/22/2022
Endpoints News , the biopharma industry’s leading source for daily news and analysis, today unveiled the 2022 Endpoints 11 — the most promising biotech startup companies of the year.
-
Six months after its launch, Vesalius Therapeutics is laying off 43% of its staff. With a current staff of 67, the company is slashing 29 jobs.
-
Current Biologics names chief executive
9/20/2022
The board of Current Biologics has selected Tom Hochuli as chief executive officer of the startup company, which is focused on providing cell and gene therapy manufacturing and development services to the biotechnology and pharmaceutical industries.
-
Gettysburg Cancer Center Rebrands as Pennsylvania Cancer Specialists & Research Institute
9/20/2022
Gettysburg Cancer Center, a leading community oncology practice in Pennsylvania for three decades, unveiled a new name and logo as part of an extensive rebrand and opened their new clinic at 6475 Carlisle Pike, Mechanicsburg, where the practice's founder and medical director, Satish Shah, MD, and Jasmine Ross, MD are treating patients.
-
Biohaven Announces Record Date for Anticipated Spin-Off
9/19/2022
Biohaven Pharmaceutical Holding Company Ltd. announced that it has set a record date of September 26, 2022 for the previously announced spin-off by Biohaven of its Biohaven Ltd. subsidiary, which will own the Kv7 ion channel activators, glutamate modulation, myeloperoxidase inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by Biohaven.
-
With a distinct take on CRISPR, Carver Biosciences secured seed financing to support the development of RNA-targeting gene therapies aimed at RNA-based respiratory infectious diseases.
-
Gala Therapeutics and Galaxy Medical will be folded into Galvanize Therapeutics to continue to develop their electric pulse therapies for bronchitis, cardiac arrhythmias and solid tumors.
-
With $165 million in the bank, Capstan launched Wednesday to combine the potency of cell therapy with the precision of genetic medicines against various difficult-to-treat diseases.
-
Pretzel Therapeutics launched Monday with $72.5 million in Series A financing to develop novel, mitochondria-based therapies to treat rare genetic disorders and diseases of aging.
-
Orbital Therapeutics, co-founded by John Maraganore, launched with the goal of harnessing the full potential of RNA-based therapeutics to tackle diseases in a new and more effective manner.